



ASX RELEASE

Recruitment complete for all forty subjects in Paradigm's hay fever clinical trial

Key Highlights:

- All clinical trial subjects (n=40) have been recruited into the Phase 2a clinical trial;
- Treatment has commenced in 30 subjects;
- Last patient out of the study by 31 March, 2017.

Melbourne: 25 November 2017 Paradigm Biopharmaceuticals Ltd (ASX:PAR) announces recruitment of all clinical trial subjects (n=40) is complete.

PHASE 2a CLINICAL TRIAL: The Company is delighted to provide an update on its Phase 2a clinical trial in Lund, Sweden. The Phase 2a clinical trial is an allergen challenge study in subjects with allergic rhinitis (hay fever). It is a double blind, placebo controlled, cross over clinical trial design being conducted in 40 subjects.

RECRUITMENT COMPLETE AND TREATMENT BEGUN: The first group of 15 clinical trial subjects will finish treatment in two weeks, the second group of 15 clinical trial subjects will finish treatment by mid-March, and the third group of 10 clinical trial subjects will finish treatment by end of March 2017. Last subject out of the study is scheduled for 31 March, 2017 with a readout of results anticipated in late Q2 or early Q3 CY2017.

The trial is being conducted under the leadership of Dr Lennart Greiff at Skane University Hospital who has previously conducted similar clinical trials, using the established allergen challenge clinical model for allergic rhinitis, for Big Pharma including Astra Zeneca.

The Company is pleased with the progress of the Phase 2a clinical trial and it confirms the clinical trial is on schedule and on budget.

ADDRESSABLE MARKET: The current market for Allergic Rhinitis is about USD 11 Billion* and is dominated by anti-histamines and corticosteroids with market surveys highlighting patient dissatisfaction and the need for effective therapy. Rhinosul® has unique properties consisting of both histamine stabilising and non-steroidal anti-inflammatory properties without the known side-effects of anti-histamines and steroids. The company believes its product can meet market needs that are not effectively managed by current nasal sprays.

About Paradigm Biopharmaceuticals Ltd: (ABN: 94 169 346 963) Paradigm Biopharmaceuticals Ltd

(ASX: PAR) is an Australian biopharmaceutical company focused on repurposing the historic drug PPS (Pentosan Polysulfate Sodium) as a potential new treatment for Bone Marrow Edema (BME) lesions following traumatic injury. Paradigm Biopharmaceuticals is also repurposing PPS for respiratory diseases including Allergic Rhinitis (AR) also known as hay fever. Paradigm is also investigating the use of PPS to treat viral arthritis following mosquito born alphavirus infections such as Ross River and Chikungunya. Repurposing an existing drug diminishes early developmental risks associated with traditional new drug development and usually means shorter development times, lower development costs and less safety risk.

<http://paradigmbiopharma.com> or email enquiries to: info@paradigmbiopharma.com

^x Visiongain: Allergic Rhinitis Drugs Market Forecast 2015-2025